Posttranslational modification of β-catenin is associated with pathogenic fibroblastic changes in bronchopulmonary dysplasia

Am J Physiol Lung Cell Mol Physiol. 2017 Feb 1;312(2):L186-L195. doi: 10.1152/ajplung.00477.2016. Epub 2016 Dec 9.

Abstract

Bronchopulmonary dysplasia (BPD) is a common complication of premature birth. The histopathology of BPD is characterized by an arrest of alveolarization with fibroblast activation. The Wnt/β-catenin signaling pathway is important in early lung development. When Wnt signaling is active, phosphorylation of β-catenin by tyrosine kinases at activating sites, specifically at tyrosine 489 (Y489), correlates with nuclear localization of β-catenin. We examined fetal lung tissue, lung tissue from term newborns, and lung tissue from infants who died with BPD; we found nuclear β-catenin phosphorylation at Y489 in epithelial and mesenchymal cells in fetal tissue and BPD tissue, but not in the lungs of term infants. Using a 3D human organoid model, we found increased nuclear localization of β-catenin phosphorylated at Y489 (p-β-cateninY489) after exposure to alternating hypoxia and hyperoxia compared with organoids cultured in normoxia. Exogenous stimulation of the canonical Wnt pathway in organoids was sufficient to cause nuclear localization of p-β-cateninY489 in normoxia and mimicked the pattern of α-smooth muscle actin (α-SMA) expression seen with fibroblastic activation from oxidative stress. Treatment of organoids with a tyrosine kinase inhibitor prior to cyclic hypoxia-hyperoxia inhibited nuclear localization of p-β-cateninY489 and prevented α-SMA expression by fibroblasts. Posttranslational phosphorylation of β-catenin is a transient feature of normal lung development. Moreover, the persistence of p-β-cateninY489 is a durable marker of fibroblast activation in BPD and may play an important role in BPD disease pathobiology.

Keywords: Wnt/β-catenin; bronchopulmonary dysplasia; disease modeling; fibrosis; hyperoxia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural

MeSH terms

  • Actins / metabolism
  • Bronchopulmonary Dysplasia / metabolism*
  • Bronchopulmonary Dysplasia / pathology*
  • Cell Nucleus / drug effects
  • Cell Nucleus / metabolism
  • Dasatinib / pharmacology
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism*
  • Fibroblasts / pathology*
  • Humans
  • Hyperoxia / complications
  • Hyperoxia / metabolism
  • Hyperoxia / pathology
  • Hypoxia / complications
  • Hypoxia / metabolism
  • Hypoxia / pathology
  • Infant, Newborn
  • Lung / drug effects
  • Lung / growth & development
  • Lung / metabolism
  • Lung / pathology
  • Organoids / drug effects
  • Organoids / metabolism
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / pharmacology
  • Protein Processing, Post-Translational* / drug effects
  • Protein Transport / drug effects
  • Up-Regulation / drug effects
  • Wnt Signaling Pathway / drug effects
  • beta Catenin / metabolism*

Substances

  • Actins
  • Protein Kinase Inhibitors
  • beta Catenin
  • Dasatinib